TNF registered in Europe: does TNF get a second chance?
AMM Eggermont - Journal of Immunotherapy, 2000 - journals.lww.com
Tumor necrosis factor-alpha (TNF-alpha) has been approved by the European Medicine
Evaluation Agency for application in the setting of isolated limb perfusion (ILP) in
combination with melphalan for locally advanced or irresectable grade II–III soft tissue
sarcomas of the extremities. The registration file consisted of 270 ILPs in 246 patients
because 24 patients underwent 2 ILPs. After review by two independent committees, 196
patients were consideredtrue candidatesfor the procedure to avoid an amputation because …
Evaluation Agency for application in the setting of isolated limb perfusion (ILP) in
combination with melphalan for locally advanced or irresectable grade II–III soft tissue
sarcomas of the extremities. The registration file consisted of 270 ILPs in 246 patients
because 24 patients underwent 2 ILPs. After review by two independent committees, 196
patients were consideredtrue candidatesfor the procedure to avoid an amputation because …